Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary arterial hypertension. MRE-269(ACT-333679) is an active metabolite of Selexipag (S253150).
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 11,000 | |||
10 mg | 在庫あり | ¥ 20,500 | |||
25 mg | 在庫あり | ¥ 33,000 | |||
50 mg | 在庫あり | ¥ 45,000 | |||
100 mg | 在庫あり | ¥ 76,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 12,000 |
説明 | MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary arterial hypertension. MRE-269(ACT-333679) is an active metabolite of Selexipag (S253150). |
ターゲット&IC50 | IP receptor (human):20 nM(Ki) |
別名 | MRE 269, ACT-333679, MRE269 |
分子量 | 419.52 |
分子式 | C25H29N3O3 |
CAS No. | 475085-57-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (131.1 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MRE-269 475085-57-5 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor MRE 269 inhibit ACT333679 Inhibitor ACT-333679 MRE269 ACT 333679 inhibitor